Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 14/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.43 |
| ▸ | PTGDR | Q13258 | 6/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16480414 | 0.85 | BRD4 (0.44) | PTGER2PTGER3PTGDRBRD4CREBBP | |
| SCHEMBL9891739 | 0.84 | BRD4 (0.39) | PTGER2PTGER3PTGDRBRD4CREBBP | |
| SCHEMBL9893020 | 0.83 | PTGER2 (0.42) | PTGER2PTGER3PTGDRPTGER4 | |
| SCHEMBL9106214 | 0.83 | HDAC6 (0.39) | PTGER2PTGER3PTGDRBRD4CREBBP | |
| SCHEMBL2572517 | 0.83 | HDAC6 (0.39) | PTGER2PTGER3PTGDRBRD4CREBBP | |
| SCHEMBL9893019 | 0.73 | PTGER2 (0.37) | PTGER2PTGER3PTGDRPTGER4 | |
| SCHEMBL8018111 | 0.72 | PAX8 (0.55) | BRD4CREBBPPAX8 | |
| SCHEMBL9102252 | 0.71 | CNR2 (0.70) | — | |
| SCHEMBL9893023 | 0.70 | PER2 (0.46) | PTGER2PTGER3PTGDR | |
| SCHEMBL9893157 | 0.70 | PTGER2 (0.42) | PTGER2PTGER3PTGDRBRD4PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | PTGER2 186/4885PTGER3 200/4885PTGDR 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.